References
- Asawanonda, P., Nateetongrungsak, Y. (2006). Methotrexate plus narrowband UVB phototherapy versus narrowband UVB phototherapy alone in the treatment of plaque-type psoriasis: A randomized, placebo-controlled study. J. Amer. Acad. Dermatol., 54, 1013–1018.
- Attwa, E. M., Elkot, R. A., Abdelshafey, A. S., Hafez, A. R. (2019). Subcutaneous methotrexate versus oral form for the treatment and prophylaxis of chronic plaque psoriasis. Dermatol Ther., 32, 13051.
- Boffa, M., Chalmers, R. (1996). Methotrexate for psoriasis. Clin. Exp. Dermatol., 21, 399–408.
- Carling, D. (2007). The role of the AMP-activated protein kinase in the regulation of energy homeostasis. Novartis Found Symp., 286, 72–81.
- European S3 guidelines (2009). European S3 guidelines in the systemic treatment of psoriasis vulgaris. J. Eur. Acad. Dermatol. Venereol., Suppl 2, 1–70.
- Goktas, E. O., Aydin, F., Senturk, N., Canturk, M. T., Turanli, A. Y. (2006). Mechanism of ultraviolet (UV) B and UVA phototherapy. JEADV, 20, 553–557.
- Griffiths, C. E., Barker, J. N. (2007). Pathogenesis and clinical features of psoriasis. Lancet, 370, 263–271.
- Hartmane, I., Mikažāns, I., Ivdra, I., Ķīsis, J. (2016). Vidēji smagas un smagas gaitas psoriāzes klīniskās vadlīnijas [Guidelines for treatment moderate and severe psoriasis] (in Latvian). https://www.spkc.gov.lv/lv/registretas-2016gada/5735c550ebf101.pdf (accessed 20.03.2024).
- Hartmane, I., Mikazans, I, Ivdra, I, Derveniece (2017). Evaluation of clinical efficacy and safety in treatment of patients with moderate and severe forms of psoriasis with combined low dose methotrexate and narrow band UVB therapy. In: Collection of Scientific Papers: Research articles in medicine & pharmacy. / Rīga Stradiņš University,- Riga, pp. 5–10. https://www.rsu.lv/en/scientific-papers/evaluation-clinical-efficacy-and-safety-treatment-patients-moderate-and-severe (accessed 20.03.2024).
- Hartmane, I., Mikažāns, I, Ivdra, I, Dērveniece, A, (2016). Experience of phototherapy in dermatological praxis in complex therapy of psoriasis patients. Proc. Latv. Acad. Sci., Section B, 70 (1), 7–12.
- Hartmane, I., Ivdra, I., Mikažāns, I., Bondare-Ansberga, V. (2021). Immunopathogenic treatment options for psoriasis patients under a restrictive reimbursement environment. Proc. Latv. Acad. Sci., Section B, 75 (3), 158–166.
- Lebwohl, M., Menter, A., Koo, J., Feldman, S. R. (2004). Combination therapy to treat moderate to severe psoriasis. J. Amer. Acad. Dermatol., 50, 416–430.
- Mahajan, R., Kaur, I., Kanwar, A. J. (2010). Methotrexate/narrowband UVB phototherapy combination vs. narrowband UVB phototherapy in the treatment of chronic plaque-type psoriasis: A randomized single-blinded placebo-controlled study, J. Eur. Acad. Dermatol. Venereol., 24 (5), 595–600
- Menter, A., Korman, N. J., Elmets, C. A., Feldman, S. R., Gelfand, J. M., Gordon, K. B., Gottlieb, A., Koo, J. Y. M., Lebwohl, M., Lim, H. W., Van Voorhees, A. S., Beutner, K. R., Bhushan, R. (2010). Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J. Amer. Acad. Dermatol., 62, 114–135.
- Paul, B. S., Momtaz, R., Stern, S., Arndt, K. A., Parrish, J. A. (1982). Combined methotrexate-ultraviolet B therapy in the treatment of psoriasis. J. Amer. Acad. Dermatol., 53, 758–762.
- Pichlmeier, U., Heuer K. U. (2014). Subcutaneous administration of methotrexate with a prefilled autoinjector pen results in a higher relative bioavailability compared with oral administration of methotrexate. Clin. Exp. Rheumatol., 32, 563–571.
- Puig, L. (2014). Methotrexate: New therapeutic approaches. Actas Dermosifiliogr, 105, 583–589.
- Rácz, E, Prens, E. P., Kurek, D., Kant, M., de Ridder, D., Mourits, S., Baerveldt, E.M., Ozgur Z., van IJcken, W. F., Laman, J. D., Staal, F. J., van der Fits, L. (2011). Effective treatment of psoriasis with narrow-band UVB phototherapy is linked to suppression of the IFN and Th17 pathways. J. Invest. Dermatol., 131 (7),1547–1558.
- Rendon, A., Schakel, K. (2019). Psoriasis pathogenesis and treatment. Int. J. Mol. Sci., 20, 1–28.
- Roubille, C., Riche, R., V., Starnino, T., McCour, T., C., McFarlane, A., Fleming, P., Siu, S., Kraft, J., Lynde, C., Pope, J., Gulliver, W., Keeling, S., Dutz, J., Bessette, L., Bissonnette, R., Haraoui, B. (2015). The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: A systematic review and meta-analysis. Ann. Rheum. Dis., 74, 480–489.
- Schmitt, J., Zhang, Z., Wozel, G., Meurer, M., Kirch, W. (2008). Efficacy and tolerability of biologic and non-biologic systemic treatments for moderate to severe psoriasis: Meta- analysis of randomized controlled trials. Brit. J. Dermatol., 159, 513–526.
- Soliman, A., Nofa A., Fatm, A., D., Asal, M. (2015). Combination therapy of methotrexate plus NBUVB phototherapy is more effective than methotrexate monotherapy in the treatment of chronic plaque psoriasis J. Dermatol. Treat., 26, 528–534.
- Tournier, A., Khemis, A., Maccari, F., Reguiai, Z., Bégon, E., Fougerousse A.C., Amy de la Breteque, M., Beneton, N., Parier, J., Boyé, T., et al. (2019). Methotrexate efficacy and tolerance in plaque psoriasis. A prospective real-life multicentre study in France. Resopso, Tournier. Ann. Dermatol. Venereol., 146, 106–114.
- Van, E. D., Diem, T. P., Thi., V. B., Thi., T. H., Xuan, T., Tuan, K.L. (2019). Successful psoriasis treatment using NB-UVB with methotrexate: The Vietnamese experience. J. Med. Sci., 27, 253–255.
- Wang, W., Zhou, H., Liu, L., Wang, W. (2018). Side effects of methotrexate therapy for rheumatoid arthritis: Asystematic review. Eur. J. Med. Chem., 158, 502–516.
- Warren, R. B., Mrowietz, U., von Kiedrowski, R., Niesmann, J., Wilsmann-Theis, D., Ghoreschi, K., Zschocke, I., Falk, T.M., Blödorn-Schlicht, N., Reich, K. (2017). An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque- type psoriasis (METOP): A 52 week, multicenter, randomized, double-blind, placebo-controlled, phase 3 trial. Lancet., 389, 528–537.
- Yan, K., Xu, W., Huang, Y. (2018). Methotrexate restores the function of peripheral blood regulatory T cells in psoriasis vulgaris via the CD73/AMPK/mTOR pathway. Brit. J. Dermatol., 179, 896–905.